Advancements in drug design have resulted in resurging interest in drugs that form covalent bonds with their targets, often referred to as targeted covalent inhibitors. Covalent drugs have the potential to provide enhanced potency and prolonged duration of action compared to non-covalent drugs. However, it is critical for covalent inhibitors to exhibit sufficient selectivity to mitigate off-target effects caused by binding to unintended proteins.
In this webinar, our speaker will introduce the unique DMPK properties of covalent drugs to support lead optimization efforts.
Join this webinar to learn:
DMPK Properties of Covalent Drugs
Research Platforms of Covalent Drugs
Related Resources
-
Discovery and Evaluation of Pyrazolo[3,4‑d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor
PublicationsMay 15,2025 -
Covalent Drugs DMPK Services
BrochuresApr 10,2025 -
Unlocking High-Throughput Bioanalysis of Covalent Drugs with Intact Protein, DSF, and Peptide Mapping Techniques
ArticlesJan 20,2025
Related Services and Platforms
Stay Connected
Keep up with the latest news and insights.